Literature DB >> 12468702

Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).

J Wright1, D Brocklebank, F Ram.   

Abstract

The research evidence on the effectiveness of inhaler devices for the treatment of asthma and chronic obstructive pulmonary disease published in a recent issue of Effective Health Care is reviewed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12468702      PMCID： PMC1758018          DOI： 10.1136/qhc.11.4.376

Source DB:  PubMed          Journal:  Qual Saf Health Care        ISSN： 1475-3898


  64 in total

1.  A cost analysis on the pattern of asthma prescribing in the UK.

Authors:  R G Neville; M G Pearson; N Richards; J Patience; S Sondhi; B Wagstaff; N Wells
Journal:  Eur Respir J       Date:  1999-09       Impact factor: 16.671

2.  Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease.

Authors:  A Ikeda; K Nishimura; H Koyama; M Tsukino; T Hajiro; M Mishima; T Izumi
Journal:  Respiration       Date:  1999       Impact factor: 3.580

3.  Safety of long-term treatment with HFA albuterol.

Authors:  J W Ramsdell; N M Klinger; B P Ekholm; G L Colice
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

4.  Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography.

Authors:  J G Goldin; D P Tashkin; E C Kleerup; L E Greaser; U M Haywood; J W Sayre; M D Simmons; M Suttorp; G L Colice; J A Vanden Burgt; D R Aberle
Journal:  J Allergy Clin Immunol       Date:  1999-12       Impact factor: 10.793

5.  Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.

Authors:  W W Busse; S Brazinsky; K Jacobson; W Stricker; K Schmitt; J Vanden Burgt; D Donnell; S Hannon; G L Colice
Journal:  J Allergy Clin Immunol       Date:  1999-12       Impact factor: 10.793

6.  Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.

Authors:  E F Juniper; A S Buist
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

7.  A new beclomethasone dipropionate multidose powder inhaler in the treatment of bronchial asthma.

Authors:  M M Nieminen; P Vidgren; J Kokkarinen; K Laasonen; K Liippo; A Lindqvist; M Paananen; A Poukkula; E Ruotsalainen; E Salomaa; A Sovijärvi; T Söderblom; M Silvasti; M Vidgren; L A Laitinen
Journal:  Respiration       Date:  1998       Impact factor: 3.580

8.  Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.

Authors:  E Bronsky; B P Ekholm; N M Klinger; G L Colice
Journal:  J Asthma       Date:  1999       Impact factor: 2.515

9.  Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma.

Authors:  J Milanowski; J Qualtrough; V L Perrin
Journal:  Respir Med       Date:  1999-04       Impact factor: 3.415

10.  Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.

Authors:  R J Davies; P Stampone; B J O'Connor
Journal:  Respir Med       Date:  1998-06       Impact factor: 3.415
View more
  13 in total

1.  Developing a Virtual Teach-To-Goal™ Inhaler Technique Learning Module: A Mixed Methods Approach.

Authors:  Meng Wu; Nicole M Woodrick; Vineet M Arora; Jeanne M Farnan; Valerie G Press
Journal:  J Allergy Clin Immunol Pract       Date:  2017-06-07

2.  Critical Inhaler Administration Errors of Patients on Pressurized Meter Dose Inhaler (pMDI): A Hospital-Based Cross-Sectional Study in Malaysia.

Authors:  Retha Rajah; Yi Woei Tang; Shien Chee Ho; Jo Lyn Tan; Muhamad Shuhaimi Mat Said; Lee Hwang Ooi
Journal:  Hosp Pharm       Date:  2021-04-21

Review 3.  Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection.

Authors:  Valentina Ruggiero; Rita P Aquino; Pasquale Del Gaudio; Pietro Campiglia; Paola Russo
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

Review 4.  Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices.

Authors:  Felix S F Ram; Celso R Carvallho; John White
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-02-02

5.  Evaluating inhaler use technique in COPD patients.

Authors:  Chaicharn Pothirat; Warawut Chaiwong; Nittaya Phetsuk; Sangnual Pisalthanapuna; Nonglak Chetsadaphan; Woranoot Choomuang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-08

6.  Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers.

Authors:  Jaime Algorta; Laura Andrade; Marta Medina; Valentin Kirkov; Sacha Arsova; Fumin Li; Jingduan Chi
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

Review 7.  Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes.

Authors:  Omar Sharif Usmani; Federico Lavorini; Jonathan Marshall; William Christopher Nigel Dunlop; Louise Heron; Emily Farrington; Richard Dekhuijzen
Journal:  Respir Res       Date:  2018-01-16

8.  Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting.

Authors:  Janine A M Westerik; Victoria Carter; Henry Chrystyn; Anne Burden; Samantha L Thompson; Dermot Ryan; Kevin Gruffydd-Jones; John Haughney; Nicolas Roche; Federico Lavorini; Alberto Papi; Antonio Infantino; Miguel Roman-Rodriguez; Sinthia Bosnic-Anticevich; Karin Lisspers; Björn Ställberg; Svein Høegh Henrichsen; Thys van der Molen; Catherine Hutton; David B Price
Journal:  J Asthma       Date:  2016-01-26       Impact factor: 2.515

Review 9.  Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.

Authors:  Jens Markus Borghardt; Charlotte Kloft; Ashish Sharma
Journal:  Can Respir J       Date:  2018-06-19       Impact factor: 2.409

10.  Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.

Authors:  Sina Saffaran; Wenfei Wang; Anup Das; Walter Schmitt; Eva-Maria Becker-Pelster; Jonathan G Hardman; Gerrit Weimann; Declan G Bates
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.